NRG-103 injection for recurrent glioblastoma patients
Part of Cancer clinical trials.
This trial tests an injection called NRG-103 given directly into the cavity where a recurrent brain tumor was removed. It is for people with glioblastoma that has come back and who have already had standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a confirmed diagnosis of recurrent glioblastoma (a type of brain tumor).
- The recurrent tumor must have been surgically removed, and a small reservoir (Ommaya) must have been placed in the cavity.
- You should be in good overall health, able to care for yourself (Karnofsky score 70 or higher), and have stable or decreasing steroid use.
- Your blood counts, liver, kidney, and heart function must be within safe limits.
- You cannot have other serious conditions like active hepatitis, severe heart disease, or a history of certain other cancers or immune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a virus-based treatment for glioblastoma that has come back after standard therapies. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone.
This trial tests a new injection called NRG-103 for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard treatments. The goal is to see if it's safe and if it might help shrink the tumor.
This trial is testing a new drug (JL15003) given directly into the brain tumor using a small device called an Ommaya reservoir. It is for people whose glioblastoma has come back despite standard treatments. You will need to have had a polio vaccine booster before starting.
This trial tests a new injection called VRT106 for people whose glioblastoma (a brain tumor) has come back or is growing. It uses a virus that may help the immune system attack the tumor. This study is for those who have not had a similar virus or gene therapy before.
This trial tests engineered immune cells (called NK cells) that are designed to fight glioblastoma, a deadly brain cancer. The cells are injected directly into the tumor and may help patients whose cancer has come back after standard treatment.
This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.